Nuclear Matrix and Cancer: Proteomic and Genomic Analyses Using Microarray in Cells Obtained Via Thoracocentesis

Accurate characterization of malignant cells obtained via thoracocentesis is of paramount importance in the management of cancer patients. The identification of novel biomarkers may in that regard considerably improve the diagnostic approach of these pleural effusions, guide therapeutic decisions, particularly with respect to targeted therapies, and offer helpful prognostic information. Nuclear anomalies represent the cornerstone of the cytologic and/or histopathologic diagnosis of malignant cells. The nuclear matrix is a fundamental constituent of the nuclear architecture via its interaction with the nuclear membrane, but is also directly involved with DNA and RNA processing. Prior studies have suggested that in some cancers, the lamins, a major constituent of the nuclear matrix, have different patterns of expression or nuclear localization that could potentially have prognostic implications. Our project aims at studying the constituents of the nuclear matrix of malignant cells isolated for pleural fluid in patients with metastatic disease, both of bronchogenic or non-bronchogenic origin, which, to our knowledge, has not yet been done. Both proteomic (localization by immunofluorescence and expression by Western-Blot) and genomic (microarray, CGH type) analyses will be undertaken to identify microrearrangements in the genes of interest. The primary aim is to identify specific biomarkers to more accurately characterize malignant cells in metastatic pleural disease.

Study Overview

• Status: Completed
• Conditions: Cancer
• Intervention / Treatment: Genetic: blood sample, thoracocentesis

• Study Type: Observational
• Enrollment (Actual): 27

Contacts and Locations

Study Locations

• France
  • Marseille, France, 13354
    • Assistance Publique Hopitaux de Marseille
  • Marseille, France, 13005
    • Assistance Publique Des Hopitaux de Marseille

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

patients with metastatic disease

Description

Inclusion Criteria:

• sign consent approval
• patients with metastatic disease, both of bronchogenic or non-bronchogenic origin
• 50% or more of malignant cells

Exclusion Criteria:

• patients with tumoral treatment during thoracocentesis
• 50% or less of malignant cells

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
patients	Genetic: blood sample, thoracocentesis; 20ml of blood only one thoracocentesis (the same that one for diagnostic)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
identify specific biomarkers to more accurately characterize malignant cells in metastatic pleural disease	Research for quantitative or qualitative nuclear-matrix-proteins anomalies in secondary metastatic pleural disease and/or for anomalies in the genes coding for these proteins. Protein analysis : immunofluorenscy, western blot. Genomic analysis : CGH arrays.	2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Variations of nuclear matrix proteins expression or localization in malignant cells released in pleural liquid		2 years
Comparison of nuclear matrix protein expression in metastatic cells	by taking account of the origin and the histological nature of the primitive tumor	2 years
Identify genomic anomalies of the interest genes	the tumoral cells genome versus the peripheral cells genome	2 years
Search existence of a correlation between the quantity of expressed proteins and the number of genes copies in the tumoral cells		2 years
Compare their results with the data published on cell-lineages and on tissular samples	Showing differences between tumor cells, cell-lineages and cells released in the liquid	2 years

Collaborators and Investigators

• Sponsor: Assistance Publique Hopitaux De Marseille
• Investigators: Principal Investigator: Patrice Roll, Assistance Publique Des Hopitaux de Marseille

Study record dates

Study Major Dates

• Study Start: May 1, 2010
• Primary Completion (Actual): May 1, 2012

Study Registration Dates

• First Submitted: May 18, 2010
• First Submitted That Met QC Criteria: January 26, 2011
• First Posted (Estimate): January 27, 2011

Study Record Updates

• Last Update Posted (Estimate): August 29, 2014
• Last Update Submitted That Met QC Criteria: August 28, 2014
• Last Verified: August 1, 2014

More Information

Terms related to this study

• Keywords: genetic; cancerology
• Other Study ID Numbers: 2010-A00295-34; 2010-01 (internal number)